T-type calcium channel blockers: a review of recent advances (2018-2025) [0.03%]
钙离子通道T型阻滞剂研究进展（2018-2025）
Yasinalli Tamboli,Laurent Ferron,Gerald W Zamponi
Yasinalli Tamboli
Introduction: T-type calcium channels are critical for a number of physiological and pathophysiological processes, and are potential molecular targets for antiepileptics, analgesics and drugs that alleviate non-essential ...
A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021 - 2025) [0.03%]
2021-2025年用于治疗不同癌症的选择性PI3Kα突变抑制剂的专利回顾
Haixiang Qi,Jiayang Wen,Heng Xu
Haixiang Qi
Introduction: Oncogenic PIK3CA mutations drive numerous solid tumors, rendering PI3Kα a key therapeutic target. However, conventional ATP-competitive inhibitors are severely limited by dose-limiting metabolic toxicities ...
A patent perspective of RSK inhibitors to treat cancers (2020 - present) [0.03%]
专利视角下RSK抑制剂的抗肿瘤研究(2020年-至今)
Aviv Preminger,Deborah A Lannigan
Aviv Preminger
Introduction: The Ser/Thr protein kinase family, p90ribosomal S6 kinase (RSK), can be activated by inputs from ERK1/2, PDK1 and in some cases MK1/MK2. Dysregulated RSK activity is implicated in diseases associated with in...
Myeloperoxidase (MPO) inhibitors: an updated patent review (2020 - present) [0.03%]
髓过氧化物酶(MPO)抑制剂：2020-至今专利回顾更新
Zhiwei Meng,Dan Chen,Xingyu Yao et al.
Zhiwei Meng et al.
Myeloperoxidase (MPO), a key enzyme involved in neutrophil extracellular trap formation and other inflammatory processes, has emerged as an attractive therapeutic target for cardiovascular, central nervous system, respiratory, and autoimmun...
Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage [0.03%]
下一代抗HSV药物解旋酶-引物酶抑制剂的研究：从临床现状到构效关系和专利布局分析
Christian Gege,Gerald Kleymann
Christian Gege
Introduction: Helicase-primase is an interesting target for small-molecule therapy of orthoherpesviruses in general and in particular herpes simplex virus (HSV) and varicella zoster virus (VZV) infections. With amenamevir...
Autotaxin inhibitors: an updated patent review (2021-present) [0.03%]
靶向_autotaxin_的抑制剂专利回顾(2021-至今)
Xiujian Wei,Chengjing Zhao,Zhi Cao et al.
Xiujian Wei et al.
Introduction: Autotaxin (ATX) inhibition has attracted considerable interest as a therapeutic strategy, resulting in more than 50 patents being published by various institutions over the past five years. Consequently, a r...
Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold [0.03%]
近年ASK1抑制剂专利布局概况及1-异丙基-4H-1,2,4-三唑-3-基-2-吡啶privileged骨架研究动态分析
Yash Kumar Gaur,Divyanshi Thakur,Shivam Nag et al.
Yash Kumar Gaur et al.
Introduction: Apoptosis signal-regulating kinase 1 (ASK1) is an important stress-responsive kinase involved in multiple pathological conditions including fibrosis, cancer, cardiovascular disorders, inflammatory diseases, ...
AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review 2020-present [0.03%]
用于癌症治疗和疗效监测的AKR1C3抑制剂和靶向药物（2020年至今）专利回顾
Alfie M Case,Melanie M Smith,Cole A Mack et al.
Alfie M Case et al.
Introduction: Aldo-keto reductase 1C3 (AKR1C3) is a drug target for the treatment of various androgen dependent malignancies, including castration-resistant prostate canceras well as hematological cancers. The enzyme play...
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present) [0.03%]
2020年以来二酪氨酸特异性磷酸化调节激酶1A(DYRK1A)抑制剂专利综述
Mennatallah Abdallah,Parthiena M Keddis,Trevina M Keddis et al.
Mennatallah Abdallah et al.
Introduction: Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a conserved CMGC serine/threonine kinase with an autophosphorylation-dependent activation mechanism. As a dosage-sensitive regulator ...
Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present) [0.03%]
塔代亚G蛋白偶联受体5和法尼醇X受体激动剂治疗糖尿病的专利综述及临床进展（2015-至今）
Shivank Sharma,Vanktesh Kumar,Shubham Kumar et al.
Shivank Sharma et al.
Introduction: Takeda G-protein-coupled receptor 5 (TGR5) and farnesoid X receptor (FXR) are bile acid-activated receptors involved in glucose, lipid, and energy homeostasis, making them promising therapeutic targets for t...